Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
367 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT02244632 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | completed | Phase 1 / Phase 2 | 105 | Isofol Medical ABINDUSTRY | 4 | Sep 9, 2020 |
| clinicaltrials |
| NCT03539484 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | terminated | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 4 | Sep 3, 2020 | clinicaltrials |
| NCT04139070 | Electrochemotherapy for Non-curable Gastric Cancer | unknown | Phase 1 | 8 | Zealand University HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03042793 | Vaccination With PD-L1 Peptide Against Multiple Myeloma | completed | Phase 1 | 10 | Lene Meldgaard KnudsenOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03199872 | RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | completed | Phase 1 / Phase 2 | 22 | RhoVac APSINDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT02592213 | Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer | unknown | Phase 1 / Phase 2 | 10 | Odense University HospitalOTHER | 1 | Jun 1, 2020 | clinicaltrials |
| NCT02316197 | Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | completed | Phase 1 | 31 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Apr 28, 2020 | clinicaltrials |
| NCT02324257 | A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors | completed | Phase 1 | 149 | Hoffmann-La RocheINDUSTRY | 7 | Apr 17, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT02912676 | Thiopurine EnhAnced Maintenance Therapy(TEAM) | completed | Phase 1 / Phase 2 | 30 | Kjeld SchmiegelowOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT04086290 | National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients(Oligomet_DK) | recruiting | Phase 1 / Phase 2 | 20 | Peter Busch ØstergrenOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP(SMR-3184) | terminated | Phase 1 / Phase 2 | 1 | Allarity TherapeuticsINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT02379195 | Peginterferon and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 12 | Inge Marie SvaneOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02264418 | Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours(KIDES-203) | completed | Phase 1 | 84 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02350673 | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02304393 | A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 140 | Hoffmann-La RocheINDUSTRY | 6 | Dec 13, 2019 | clinicaltrials |
| NCT02893137 | Enhancing Optune Therapy With Targeted Craniectomy | completed | Phase 1 | 15 | Aarhus University HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02093351 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | completed | Phase 1 | 79 | AstraZenecaINDUSTRY | 5 | Oct 2, 2019 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT03694080 | Calcium Electroporation for Early Colorectal Cancer | unknown | Phase 1 | 24 | Zealand University HospitalOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT01844947 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract(VINSOR) | completed | Phase 1 | 22 | Dr Anders UllénOTHER | 2 | Apr 26, 2019 | clinicaltrials |
| NCT01984658 | A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients | completed | Phase 1 | 10 | CytoVac A/SINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT02913443 | A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Oct 19, 2018 | clinicaltrials |
| NCT03320525 | Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)(CHITIN) | terminated | Phase 1 | 11 | Herlev HospitalOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 99 | Puma Biotechnology, Inc.INDUSTRY | 6 | Sep 26, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02575781 | A Study of SAR428926 in Patients With Advanced Solid Tumors | completed | Phase 1 | 34 | SanofiINDUSTRY | 3 | Aug 22, 2018 | clinicaltrials |
| NCT02149225 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | completed | Phase 1 | 16 | Immatics Biotechnologies GmbHINDUSTRY | 5 | Aug 7, 2018 | clinicaltrials |
| NCT03569345 | Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate | completed | Phase 1 / Phase 2 | 20 | Merete HaedersdalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01619423 | A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer(PLIANT) | completed | Phase 1 / Phase 2 | 186 | Egetis TherapeuticsINDUSTRY | 8 | Jul 6, 2018 | clinicaltrials |
| NCT00963404 | Image-Guided Tumorboost of Bladder Cancer | completed | Phase 1 / Phase 2 | 19 | University of AarhusOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT00963534 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.(LENA-BERIT) | completed | Phase 1 / Phase 2 | 51 | Lund University HospitalOTHER | 4 | Mar 12, 2018 | clinicaltrials |
| NCT02004106 | A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 110 | Hoffmann-La RocheINDUSTRY | 8 | Mar 6, 2018 | clinicaltrials |
| NCT02882581 | Metformin in Breast Cancer, Visualized With Positron Emission Tomography | completed | Phase 1 | 7 | Aarhus University HospitalOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02722551 | CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study(RELIEF) | withdrawn | Phase 1 / Phase 2 | 0 | Edwards LifesciencesINDUSTRY | 7 | Jan 9, 2018 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT01918254 | A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials